Ticagrelor
If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
Description: Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet... more
Product information "Ticagrelor"
Description: Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU). Target: P2Y Receptor, P450. Smiles: CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1. References: VAN Giezen JJ, et al. J Thromb Haemost, 2009, 7(9), 1556-1565.
| Keywords: | AR-C 126532XX, AZD6140 |
| Supplier: | TargetMol |
| Supplier-Nr: | T0179 |
Properties
| MW: | 522.57 D |
| Formula: | C23H28F2N6O4S |
Database Information
| CAS : | 274693-27-5| Matching products |
Handling & Safety
| Storage: | +4°C |
| Shipping: | +4°C (International: +4°C) |
| Signal Word: | Warning |
| GHS Hazard Pictograms: |
|
| H Phrases: | H319, H411 |
| P Phrases: | P264, P273, P280, P305+351+338, P337+313, P391, P501 |
Caution
Our products are for laboratory research use only: Not for administration to humans!
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
Viewed